Vanda Pharmaceuticals Inc. (VNDA) is in the Pharma Industry

• Sort by

• Vanda Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Corey Davis from Natexis. Please proceed. Corey Davis – Natexis Thanks very much. I guess in the meaning that you have when you have it with the FDA, what’s ambiguous about the letter that could...

  Earnings calls 2008-09-02

  Tags: Vanda Pharmaceuticals Inc.

• Vanda Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript

  Question-and-Answer Session Operator Operator instructions Your first question will come from the line of Corey Davis representing Natixis. Please Proceed. Corey Davis – Natixis Bleichroeder Thanks very much. A Geodon ZODIAC study is now out and been presented a couple times and Pfizer has done very...

  Earnings calls 2008-05-22

  Tags: Vanda Pharmaceuticals Inc.

• Vanda Pharmaceuticals Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Thank you. Operator Instructions Your first question comes from the line of Adam Greene with JP Morgan. Please proceed. Adam Greene-J P Morgan Thanks, good morning, happy Valentines Day everyone. Two questions, one I was wondering if you have any thoughts following the...

  Earnings calls 2008-04-07

  Tags: Vanda Pharmaceuticals Inc.

Additional Resources

• FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date

  ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that the FDA has accepted Vanda's resubmission of the iloperidone New Drug Application NDA. Vanda's resubmission was...

  Articles 2008-11-20

• Addiction Therapeutics Reviewed by NeuroInvestment

  NI Research today announced the release of theNovember issue of NeuroInvestment, featuring a review of pharmacologictherapeutics for addiction. The interface of the biological andsociocultural factors involved in substance abuse is reviewed foraddictions to alcohol, opioids, stimulants methamphetamines and cocaine,and nicotine. Programs under development by over 25 companies are included in...

  Articles 2008-11-14

• Vanda Pharmaceuticals Reports Third Quarter 2008 Results

  ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced financial and operational results for the third quarter ended September 30, 2008. Vanda reported research and development...

  Articles 2008-10-30

• Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights

  ROCKVILLE, Md., Sept. 25 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, announced today that the Board of Directors of Vanda Pharmaceuticals Inc. (the "Company") declared a dividend distribution of one Preferred Share...

  Articles 2008-09-25

• Vanda Pharmaceuticals Provides Update on Iloperidone

  ROCKVILLE, Md., Sept. 11 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, reported today that it met with the FDA on September 10, 2008 and discuss the iloperidone non-approvable action letter that the...

  Articles 2008-09-11

• The Daily Record News Briefs: August 6, 2008

  Bank's money orders 'missing' BCSB Bancorp Inc., the holding company for Baltimore County Savings Bank FSB, issued a "special alert" that money orders bearing the bank's name and serial numbers 01000101 through 01000599 "are missing, lost or stolen," and said it has notified the Federal Deposit Insurance...

  Articles 2008-08-06

• Sucampo Pharmaceuticals Appoints Jan Smilek Acting Chief Financial Officer

  Company Names Chief Accounting Officer to Lead Finance Team BETHESDA, Md. -- Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) announced the appointment of the company's Chief Accounting Officer, Jan Smilek, to the position of Acting Chief Financial Officer, effective immediately. Smilek replaces former Chief Financial Officer Mariam E. Morris, who...

  Articles 2008-08-01

• FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals

  SOUTH SAN FRANCISCO, Calif. -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced that Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) has received a not approvable letter for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia, from the U.S. Food and Drug Administration FDA. Vanda, the sub-licensee for iloperidone, is responsible for the...

  Articles 2008-07-28

• BellwetherReport.com Analyst Report on VNDA, SOHU, RYAAY and XOHO

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-07-28

• Neuro Sector Reviewed by NeuroInvestment

  NeuroInvestment today announced the release ofits July/August issue, which overviews the CNS sector at midyear, andpreviews the second half of 2008. The major news at midyear was theAlzheimer's data which came from high-profile programs at Elan/Wyeth and atMyriad Genetics. The issue takes a hard look at those results, and notesthe...

  Articles 2008-07-07

• BellwetherReport.com Analyst Report on URRE, GOOG, HCBK and VNDA

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

  Articles 2008-06-26

• Rockville-based Vanda, LabCorp form alliance

  Vanda Pharmaceuticals Inc., of Rockville, a biopharmaceutical company that is developing drugs to treat disorders of the central nervous system, and Laboratory Corporation of America Holdings, of Burlington, N.C., one of the world's largest providers of laboratory testing services, announced an alliance to develop and commercialize a series of diagnostic...

  Articles 2008-06-06

• LabCorp® and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests

  BURLINGTON, N.C. & ROCKVILLE, Md. -- Laboratory Corporation of America[R] Holdings (LabCorp[R]) (NYSE:LH), one of the world's leading clinical trials and genetic testing laboratories, and Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced...

  Articles 2008-06-05

• Wall Street News Alert Issues Special Alert on OCOL! May 6, 2008

  Wall Street News Alert's "stocks to watch" thismorning are: Oncolin Therapeutics (OTCBB: OCOL), Vanda Pharmaceuticals Inc.(NASDAQ: VNDA), Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM), GileadSciences, Inc. (NASDAQ: GILD). There is more important news coming from Oncolin Therapeutics (OTCBB: OCOL), and the company should have investors monitoring the stock thismorning. Yesterday after the...

  Articles 2008-05-06

• New Analyst Reports for ALBERTA OILSANDS INC, RUBICON MINERALS CORPORATION, ZOLTEK COMPANIES INC, and VANDA PHARMACEUTICALS INC

  MaybachFinancial.com is one of the fastest growingindependent and unbiased research firms in the world. Through our numerouspartnerships with many of the top investment minds in the world, we provideresearch on companies making a move in the markets. Investors seekinggenuine analyst opinions on their investments for ALBERTA OILSANDS INC(TSX-V: AOS), RUBICON...

  Articles 2008-05-05

• Md.-based Vanda Pharmaceuticals Inc. announces first-quarter net

  Vanda Pharmaceuticals Inc., of Rockville, which develops drugs to treat disorders of the central nervous system, reported a first- quarter net loss of $19.2 million, or 72 cents per diluted share, on zero revenue, compared to a net loss of $15.4 million, or 61 cents per diluted share, on zero...

  Articles 2008-05-02

• Titan Pharmaceuticals Announces Fourth Quarter and Year-End 2007 Financial Results

  Significant Clinical Development Milestones Expected in 2008; Conference Call Today at 10:30 A.M. EDT SOUTH SAN FRANCISCO, Calif. -- Titan Pharmaceuticals, Inc. (AMEX:TTP) today reported financial results for the fourth quarter and full year ended December 31, 2007. "Throughout 2007, we made significant progress in each...

  Articles 2008-03-12